Lyme disease diagnostics involve detection of the lyme disease spirochete called Borrelia burgdorferi through blood tests and diagnostic imaging. Lyme disease or lyme borreliosis is caused due to borrelia bacteria transmitted through Ixodes ricinus and Ixodes pacificus ticks. Lyme disease diagnostic kits offer advantages such as early detection, cost-effectiveness and rapid results. The growing prevalence of Lyme disease worldwide has boosted the need for efficient diagnostics.
The global Lyme Disease Diagnostics Market is estimated to be valued at US$ 1.5 Bn in 2023 and is expected to exhibit a CAGR of 3.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rapid commercialization of rapid diagnostic tests for Lyme disease is one of the key trends driving growth of the lyme disease diagnostics market. These tests can provide results within 15-30 minutes, enabling quick diagnosis and treatment initiation in tick-bite patients. Major players are focused on developing novel rapid kits with higher sensitivity and specificity. This is expected to make lyme disease diagnosis more convenient and affordable. Wider adoption of such rapid tests will boost the lyme disease diagnostics market during the forecast period.
Segment Analysis
The global lyme disease diagnostics market is dominated by the serology tests segment. This segment uses different types of serological tests like enzyme-linked immunosorbent assay (ELISA), Western blot and immunofluorescence assay (IFA) to detect IgG and IgM antibodies produced by the body's immune system in response to Borrelia burgdorferi infection. Serology tests are preferred for lyme disease diagnosis due to their high sensitivity and availability as compared to other segments like immunoblot tests, molecular diagnosis tests (polymerase chain reaction), and other testing methods.
Key Takeaways
The global lyme disease diagnostics market is expected to witness high growth over the forecast period of 2023 to 2030. The growing incidence of lyme disease across various parts of the world and increasing awareness regarding early diagnosis are key factors anticipated to drive market growth.
Regional analysis: The North America region currently dominates the market due to high lyme disease disease incidence rates in the United States. As per the Centers for Disease Control and Prevention (CDC), approximately 476,000 Americans are diagnosed with lyme disease each year. Europe is also expected to witness significant growth owing to rising lyme disease cases across various countries.
Key players operating in the lyme disease diagnostics market are Abbott Laboratories, Immunetics Inc., Bio-Rad Laboratories, Roche Diagnostics International Ltd., Siemens AG and T2 Biosystems. Abbott Laboratories offers a wide range of lyme disease diagnostic tests like ELISA kits, Western blot kits and other testing instruments.
No comments:
Post a Comment